Pilot Study of CTC Enumeration and AR-V7 Detection Using a Microporous Chip filtration system in Metastatic Prostate Cancer.

We report a translational pilot study evaluating circulating tumor cell (CTC) enumeration and androgen receptor splice variant 7 (AR-V7) detection using a microporous chip–based liquid biopsy platform combined with droplet digital PCR. The study integrates innovative diagnostic technology with clinically meaningful outcomes in patients with metastatic prostate cancer, directly aligning with the journal’s emphasis on prostate cancer biology, biomarkers, and precision therapeutics. By demonstrating the feasibility and potential clinical utility of a minimally invasive assay to assess CTC burden and molecular resistance mechanisms, this work contributes to improving patient stratification and treatment decision-making in advanced disease. The findings are particularly relevant to urologists and oncologists seeking practical biomarker-driven approaches that can be implemented in real-world clinical settings, reinforcing the journal’s mission to bridge translational research and clinical practice in prostate cancer.